

ATTORNEY DOCKET NO. 14014.0312 PATENT

MP-1644

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)		
111 10 2	Application of)		OCT 0 3 2001
Kelsall et al.)		
)	Group Art Unit: 1644	TECH CENTER 1600/2900
Serial No. 09/196,867)		
)	Examiner: DeCloux, A.	
Filed: November 20, 1998)		
)		
For:	METHODS OF USING CR3 AND CR4)		
	LIGANDS FOR INHIBITING)		
	INTERLEUKIN-12 TO TREAT)		
	AUTOIMMUNE DISEASE)		

COMMUNICATION

Assistant Commissioner for Patents Washington, D.C. 20231

NEEDLE & ROSENBERG, P.C. Suite 1200, The Candler Building 127 Peachtree Street, N.E. Atlanta, Georgia 30303-1811

September 26, 2001

Sir:

This communication is supplemental to the response filed on August 7, 2001 regarding the above-identified patent application. In that response, applicants submitted an unsigned Declaration Under 37 C.F.R. § 1.131 of Drs. Brian Kelsall, Warren Strober, Thomas Marth and Ivan Fuss as Exhibit I. Included herewith is a copy of the previously submitted Declaration Under 37 C.F.R. § 1.131 which has been executed by the declarants. Applicants respectfully request that the signed Declarations Under 37 C.F.R. § 1.131 be substituted for the unsigned Declaration Under 37 C.F.R. § 1.131 included with the August 7, 2001 Response as Exhibit I.

ATTORNEY DOCKET NO. 14014.0312 Serial No. 09/196,867

The Examiner is invited and encouraged to directly contact the undersigned if such contact may enhance the efficient prosecution of this application to issue.

No fee is believed due. However, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.

Mary L. Miller

Registration No. 39,303

NEEDLE & ROSENBERG, P.C. Suite 1200, The Candler Building 127 Peachtree Street, N.E. Atlanta, Georgia 30303-1811 (404) 688-0770

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date below.

Mary L. Miller

Date